These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8632761)

  • 1. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
    Zhang X; Smith CD
    Mol Pharmacol; 1996 Feb; 49(2):288-94. PubMed ID: 8632761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
    Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
    Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
    Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
    Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
    Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
    Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance.
    Smith CD; Zilfou JT; Stratmann K; Patterson GM; Moore RE
    Mol Pharmacol; 1995 Feb; 47(2):241-7. PubMed ID: 7870031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides.
    Zhang X; Minale L; Zampella A; Smith CD
    Cancer Res; 1997 Sep; 57(17):3751-8. PubMed ID: 9288783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
    Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
    Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
    Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
    Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
    Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
    Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
    Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol).
    Long BH; Carboni JM; Wasserman AJ; Cornell LA; Casazza AM; Jensen PR; Lindel T; Fenical W; Fairchild CR
    Cancer Res; 1998 Mar; 58(6):1111-5. PubMed ID: 9515790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
    Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule disruption induced in vivo by alkylation of beta-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents.
    Legault J; Gaulin JF; Mounetou E; Bolduc S; Lacroix J; Poyet P; Gaudreault RC
    Cancer Res; 2000 Feb; 60(4):985-92. PubMed ID: 10706114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
    Locke V; Davey R; Davey M
    Cytometry; 2001 Mar; 43(3):170-4. PubMed ID: 11170102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
    Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM
    Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide.
    Fujiwara K; Koike H; Ohishi Y; Shirafuji H; Kohno I; Modest EJ; Kataoka S
    Anticancer Res; 1997; 17(3C):2159-67. PubMed ID: 9216681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
    ter Haar E; Hamel E; Balachandran R; Day BW
    Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.